{"id":15923,"date":"2022-03-13T12:41:45","date_gmt":"2022-03-13T11:41:45","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15923"},"modified":"2022-03-13T12:41:45","modified_gmt":"2022-03-13T11:41:45","slug":"confirmation-a-long-termes-de-lefficacite-du-brentuximab-vedotin-en-premiere-ligne-des-lymphomes-t-anaplasiques-alk-et-alk","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/confirmation-a-long-termes-de-lefficacite-du-brentuximab-vedotin-en-premiere-ligne-des-lymphomes-t-anaplasiques-alk-et-alk\/","title":{"rendered":"Confirmation \u00e0 long termes de l\u2019efficacit\u00e9 du brentuximab vedotin en premi\u00e8re ligne des lymphomes T  anaplasiques ALK + et ALK \u2013"},"content":{"rendered":"<p>R\u00e9f :HematoStat.net ; 2 (3) : V43<\/p>\n<p><em>\u00a0<\/em><\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34921960\/\"><em>The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cellymphoma<\/em><\/a><\/p>\n<p><a href=\"https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002\"><em>https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002<\/em><\/a><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>R\u00e9f :HematoStat.net ; 2 (3) : V43 \u00a0 The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cellymphoma https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002 &nbsp;<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[11],"tags":[],"ppma_author":[442],"class_list":["post-15923","post","type-post","status-publish","format-standard","hentry","category-veille-bibliographique","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15923"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15923\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15923"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15923"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15923"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}